Genprex to Participate at BIO Europe Spring 2026
Rhea-AI Summary
Genprex (NASDAQ: GNPX) announced that its executive leadership will attend BIO Europe Spring in Lisbon, Portugal, March 23-25, 2026. Attendees include Ryan Confer, President and CEO, and Thomas Gallagher, SVP of Intellectual Property and Licensing.
Genprex said executives will be available for one-on-one meetings to provide overviews of the company’s gene therapy programs for cancer and diabetes; meeting requests can be made via the conference portal or investors@genprex.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows 2 peers (e.g., APRE, CLDI) moving down, with a median move of -2.4%, indicating broader sector dynamics rather than company-specific pressure.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | IP expansion | Positive | +27.5% | Japanese and EU patent grants for REQORSA combination cancer therapies. |
| Feb 10 | Patent progress | Positive | -1.8% | IP Australia intent to grant REQORSA patent with PD-L1 antibodies. |
| Jan 07 | Diabetes update | Positive | +0.0% | Clinical update on GPX-002 diabetes program and regulatory planning steps. |
| Jan 06 | Preclinical data | Positive | +5.0% | Positive preclinical proof-of-concept data for GPX-002 in T2D models. |
| Nov 24 | Trial publication | Positive | -6.7% | Publication of Acclaim-1 Phase 1 data showing safety and early efficacy. |
Positive clinical and IP updates have produced mixed reactions: some strong gains, occasional selloffs, and flat days, suggesting inconsistent follow-through on good news.
Recent news has centered on strengthening Genprex’s gene therapy pipeline and intellectual property. In Nov 2025, Acclaim-1 Phase 1 data in lung cancer showed no dose-limiting toxicities and set an RP2D, yet shares fell. In Jan 2026, encouraging GPX-002 diabetes preclinical data drove a modest gain. Patent wins reported in Feb 2026 generated both a sharp rise and a slight decline on different days. Against this backdrop, today’s conference-participation news is more visibility-focused than a clear clinical or IP catalyst.
Market Pulse Summary
This announcement highlights Genprex’s plan to attend BIO Europe Spring 2026, where executives aim to hold one-on-one meetings and showcase its gene therapies for cancer and diabetes. Recent history includes IP expansions for REQORSA and encouraging GPX-002 preclinical data, alongside restored Nasdaq equity compliance. Investors may watch for follow-up disclosures on partnerships, trial progress, and additional IP developments that could emerge from or around this conference activity. Shares remain far below the 52-week high of 55.
AI-generated analysis. Not financial advice.
In attendance will be Ryan Confer, President and Chief Executive Officer at Genprex and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex. Throughout the duration of the conference, Genprex executives will be available to conduct one-on-one meetings with industry groups to provide an overview of the Company's gene therapies for cancer and diabetes.
For those interested in meeting with Genprex management during the conference, please request a meeting through the conference meeting portal or by contacting Investor Relations at investors@genprex.com. BIO Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts. The event is expected to bring together more than 3,700 executives from biotech, pharma and finance companies to engage in more than 20,000 one-on-one meetings.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-participate-at-bio-europe-spring-2026-302709074.html
SOURCE Genprex, Inc.
FAQ
When will Genprex (GNPX) attend BIO Europe Spring 2026 in Lisbon?
Which Genprex executives will participate at BIO Europe Spring 2026?
How can investors request a meeting with Genprex (GNPX) at BIO Europe Spring?
What topics will Genprex (GNPX) discuss at BIO Europe Spring 2026?
How large is the BIO Europe Spring conference Genprex is attending?
Will Genprex (GNPX) host public presentations at BIO Europe Spring 2026?
